{"i": ["HAART comprising AZT", "TDF - based HIV - treatment", "TDF / FTC - based", "anti - retroviral therapy ( ART )", "AZT", "TDF therapy", "ABC / 3TC - based", "FRAX \u00ae tool", "thymidine", "lamivudine ( 3TC ) or emtricitabine ( FTC )", "Highly active anti - retroviral therapy ( HAART )", "DXA", "bisphosphonate , vitamin D and calcium", "abacavir", "TDF / FTC or ABC / 3TC - based treatment", "ABC - or TDF - based therapy", "Abacavir or Tenofovir Based Therapy", "tenofovir - based combination anti - retroviral therapy", "zidovudine / lamivudine ( AZT / 3TC ) to abacavir / lamivudine ( ABC / 3TC ) or tenofovir / emtricitabine ( TDF / FTC ).", "AZT to ABC", "corticosteroid therapy", "Zidovudine / lamivudine", "ABC / 3TC .", "TDF", "TDF - containing with non - TDF containing HAART - regimes", "systemic corticosteroids , bisphosphonates , vitamin D , calcium or other therapies", "HAART", "tenofovir ( TDF )/ emtricitabine ( FTC ) or abacavir ( ABC )/ lamivudine ( 3TC )", "Efavirenz", "TDF - or ABC - based", "ABC / 3TC", "Zidovudine to Tenofovir or Abacavir", "TDF / FTC", "abacavir and tenofovir", "zidovudine ( AZT )/ 3TC to ABC / 3TC or TDF / FTC .", "Nevirapine", "ABC / 3TC - based treatment", "ABC - or TDF - based", "tenofovir and abacavir"], "o": ["plasma P1NP", "bone turnover biomarker", "eCrCl nor plasma cysC", "osteoprotegerin ( OPG", "interleukin - 6 ( IL - 6 ) and high sensitive C - reactive protein ( hs - CRP )", "Bone turnover markers", "plasma creatinine and phosphate levels", "Levels of P1NP", "eCrCl estimate", "BMD decline", "bone turnover except OPG", "lumbar spine BMD", "bone turnover biomarkers except osteoprotegerin", "urine creatinine concentration", "bone formation , osteocalcin ( OC ) and procollagen type 1 N - terminal propeptide ( P1NP ;)", "creatinine clearance ( eCrCl ).", "bone mass density ( BMD ) and bone turnover biomarkers ( osteocalcin , osteocalcin , procollagen type 1 N - terminal propeptide ( P1NP ), alkaline phosphatase , type I collagen cross - linked C - telopeptide ( CTx ), and osteoprotegerin ).", "mean percentage change", "Concurrent inflammation", "Plasma levels of type I collagen cross - linked C - telopeptide ( CTx ),", "markers of proximal tubule dysfunction", "Plasma alkaline phosphatase levels", "blood pressure", "allergic skin reaction", "Biomarkers of bone turnover", "incident fractures", "Urinary albumin", "renal tubular function", "CTx", "resolved episode of pyelonephritis", "Serum and plasma", "bone turnover biomarkers", "insulin sensitivity .", "urine NGAL / creatinine", "Efficacy and Safety", "loss of BMD", "OPG", "urinary creatinine", "BMD .", "changes in BMD", "inflammatory biomarkers , hs - CRP and IL - 6 .", "BMD loss .", "fractures", "urinary NGAL / creatinine ratio", "grade 3 or 4 adverse advents", "renal function by estimated creatinine clearance , plasma cystatin C , and urinary levels of creatinine , albumin , cystatin C , and neutrophil gelatinase - associated lipocalin ( NGAL ).", "osteocalcin", "eGFR , creatinine clearance or other renal endpoints", "GFR .", "rate of bone resorption and formation", "hip and spine T scores", "cysC based GFR", "renal effects", "biomarkers of renal dysfunction", "reduction in BMD", "BMD reductions", "albumin / creatinine ratio", "Renal function parameters", "ratio", "24 - hour urine collections", "biochemical parameters of renal function", "OC and OPG", "grade 2 adverse advents", "mean percentage change in hip and lumbar spine BMD", "urinary biomarkers", "Mean systolic blood pressure (", "total hip and lumbar spine BMD", "bone and renal function", "hip and lumbar spine BMD", "BMD", "plasma levels of cysC", "Plasma and urinary cysC", "plasma phosphate levels", "renal function assessed by cystatin C ( cysC ), creatinine clearance ( CrCl ) and markers of tubule function ; bone mass density and bone metabolism assessed by DXA and bone turnover markers ; lipodystrophy and body composition assessed by DXA and patient questionnaire", "fracture risk", "plasma cysC", "bone turnover markers", "levels of 25 - OH D2 / D3 vitamin D in serum", "levels of bone turnover markers and change in BMD .", "bone and renal biomarkers", "estimated glomerular filtration rate ( GFR )", "urinary cysC / creatinine ratio", "albumin , cysC , and NGAL levels", "Bone and Renal Effects", "plasma osteocalcin ( IQR", "24 - hour excretion of albumin , tubular markers , and the fractional phosphate excretion .", "retinol - binding protein and \u03b2 - 2 microglobulin", "renal function and bone mass density", "Mean hip BMD", "P1NP", "impaired tubular function", "markers of bone turnover", "alkaline phosphatase", "Mean fasting plasma glucose", "plasma phosphate", "blood pressure , CD4 + cell counts , viral load", "urinary levels of creatinine , albumin , cysC , and neutrophil gelatinase - associated lipocalin ( NGAL )", "proportion of females", "eCrCl or plasma cysC", "bone mineral density ( BMD )", "BMD and renal and bone biomarkers", "BMD loss", "eCrCl", "levels of bone and renal biomarkers", "osteopenia and osteoporosis", "risk of fracture", "bone loss", "renal dysfunction", "clinical renal impairment", "plasma creatinine", "Plasma cysC", "bone turnover", "Urinary NGAL concentration", "renal function", "NGAL", "adverse renal effects", "bone mass density .", "Mean diastolic blood pressure", "T scores", "Mean lumbar spine BMD", "CD4 + cell count"]}